Skip to main content
Clinical Trials/NCT01353846
NCT01353846UnknownPhase 4

Comparison Between Natural and Artificial Cycle in Recipient Oocyte Patients

Instituto Valenciano de Infertilidad, IVI VALENCIA1 site in 1 country70 target enrollmentStarted: May 2011Last updated:
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 4
Sponsor
Enrollment
70
Locations
1
Primary Endpoint
Preparation and treatment for Assisted Human Reproduction procedures and in the case opf pregnancy, follow up.

Study Overview

Brief Summary

The purpose of this study is to compare the natural cycle (without any medication) with the well-established artificial cycle in an egg donation program.

Detailed Description

Oocyte donation is an assisted reproduction technique well established. In patients with ovarian function, it is necessary to synchronize the cycle of the egg donor with the recipient, usually through endometrial preparation of the recipient by artificial cycle, by administering a GnRH agonist on day 21 of cycle and then administered increasing doses of estrogen therapy to achieve adequate endometrial thickness.

The necessity of synchronization between donors and recipient, has made possible not routinely the natural cycle for oocyte donation.

The investigators have recently introduced oocyte vitrification and it allows us to plan the egg donation in a different way. Now the investigators can previously cryopreserved donor oocytes and at the time that the investigators have a compatible receiver, then, plan the donation In this study it will be possible compare the results of oocyte donation cycles in terms of pregnancy rate, implantation and liveborn, depending on whether the recipient has made an artificial cycle of preparation endometrial or a natural cycle.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to 44 Years (Adult)
Sex
Female
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • infertile females with preserved gonadal function
  • ages 18 - 44 years old included
  • first oocyte donation cycle

Exclusion Criteria

  • BMI: > 28
  • recurrent miscarriages (3 or more)
  • recurrent of implantation failure
  • severe male factor
  • important miomas
  • > 44 years old
  • Problems with the drugs used in the study

Arms & Interventions

Natural cycle

Active Comparator

Intervention: observation natural cycle (Other)

Artificial cycle

Active Comparator

Drugs: Agonist GnRH Acetate Triptoreline Acetate Triptorelina (Agonist GnRH), 3.75 mg. single dose. Estradiol Valerate, orally Initially 4 pills daily during 4 days, and after increase the dose to 6 mg orally daily.

Natural micronized progesterone, 400 mg/12 hours vaginal administration

Intervention: Agonist GnRH; estradiol Valerate; progesterone (Drug)

Outcomes

Primary Outcomes

Preparation and treatment for Assisted Human Reproduction procedures and in the case opf pregnancy, follow up.

Time Frame: 12 months

Outcome of the study is measured by the pregnancy rates after IVF treatments of both arms.

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
Instituto Valenciano de Infertilidad, IVI VALENCIA
Sponsor Class
Other

Study Sites (1)

Loading locations...

Similar Trials